Misuse of Drugs (Miscellaneous
Amendments) (No. 6) (Jersey) Order 2016
Made 17th February 2016
Coming into force 24th
February 2016
THE MINISTER FOR HEALTH AND SOCIAL SERVICES, in pursuance of Articles 3,
12, 13 and 27 of the Misuse of Drugs (Jersey) Law 1978[1], and on the recommendation of the
Advisory Council on the Misuse of Drugs, orders as follows –
1 Misuse of Drugs (Jersey) Law 1978
amended
In the Misuse of Drugs (Jersey) Law 1978[2] –
(a) in
Part 1 of Schedule 2 –
(i) in
paragraph 1(a) –
(A) before the substance “1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine”
there is inserted the substance “1-Cyclohexyl-4-(1,2diphenylethyl)piperazine
(MT-45)”,
(B) after the substance
“2, 5-Dimethoxy-α, 4-dimethylphenethylamine” there is inserted
the substance “2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone
(LSZ)”,
(C) after the substance
“2-Methyl-3-morpholino-l, l-diphenylpropanecar-boxylic acid” there
is inserted the substance “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
(AH-7921)”,
(D) after the substance “4-Methyl-aminorex”
there is inserted the substance “4-Methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine
(4,4’-DMAR)”,
(E) after the substance
“4-Phenylpiperidine-4-carboxylic acid ethyl ester” there are inserted
the following substances –
“(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ALD-52)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(PRO-LAD)”,
(ii) for
paragraph 1(b) there is substituted the following
sub-paragraph –
“(b) any compound (not being a
compound for the time being specified in sub-paragraph (a)) structurally
derived from tryptamine or from a ring-hydroxy tryptamine by modification in
any of the following ways, that is to say –
(i) by
substitution at the nitrogen atom of the sidechain to any extent with alkyl or
alkenyl substituents, or by inclusion of the nitrogen atom of the side chain
(and no other atoms of the side chain) in a cyclic structure,
(ii) by
substitution at the carbon atom adjacent to the nitrogen atom of the side chain
with alkyl or alkenyl substituents,
(iii) by
substitution in the 6-membered ring to any extent with alkyl, alkoxy,
haloalkyl, thioalkyl, alkylenedioxy, or halide substituents,
(iv) by
substitution at the 2-position of the tryptamine ring system with an alkyl substituent;”;
(b) in
Part 2 of Schedule 2 –
(i) in
paragraph 1(a) –
(A) after the substance “Codeine”
there is inserted the substance “3,4-Dichloromethylphenidate (3,4-DCMP)”,
(B) after the substance
“(3-ethylmorphine)” there is inserted the substance “Ethylnaphthidate”,
(C) after the substance
“Glutethimide” there is inserted the substance “Isopropylphenidate
(IPP or IPPD)”,
(D) after the substance “Lefetamine”
there is inserted the substance “Lisdexamphetamine”,
(E) after the substance
“Methcathinone” there are inserted the following
substances –
“4-methylmethylphenidate
Methylnaphthidate (HDMP-28)”,
(F) after the substance
“N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)” there is inserted the substance “N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)”,
(G) after the substance
“Propiram” there is inserted the substance “Propylphenidate”,
(ii) after
paragraph 1(l) there is added the following sub-paragraph –
“(m) any compound (not being
clonitazene, etonitazene, nabilone, zafirlukast, or a compound for the time
being specified in sub-paragraphs (c) to (gd)) structurally related to
1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that
is to say the indole ring, the pentyl substituent, the methanone linking group
and the naphthyl ring, are linked together in a similar manner, whether or not
any of the sub-structures have been modified, and whether or not substituted in
any of the linked sub-structures with one or more univalent substituents and
where the modifications of the sub-structures are limited to any the following,
that is to say –
(i) replacement
of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole,
benzimidazole, or pyrazolo(3,4-b)pyridine,
(ii) replacement
of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl, or
(tetrahydropyran-4-yl)methyl,
(iii) replacement
of the methanone linking group with an ethanone, carboxamide, carboxylate,
methylene bridge or methine group,
(iv) replacement
of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl,
cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl,
1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1
amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, or piperazinyl.”.
2 Misuse
of Drugs (Designation) (Jersey) Order 1989 amended
In the Schedule to the Misuse of Drugs (Designation) (Jersey) Order 1989[3] –
(a) in
Part 1 –
(i) in
paragraph 1(a) –
(A) after the substance “1,4-butanediol”
there is inserted the substance “1-Cyclohexyl-4-(1,2diphenylethyl)piperazine
(MT-45)”,
(B) after the word “Cannabis” there are inserted the
words “(not being the substance specified in
paragraph 4 of Part 2 of this Schedule)”,
(C) after
the substance “2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol”
there is inserted the substance “2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone
(LSZ)”,
(D) after
the substance “2-Methoxyethyl(α-methyl-3,4-methylenedioxyphenethyl)amine”
there are inserted the following substances –
“3,4-Dichloromethylphenidate
(3,4-DCMP)
3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
(AH-7921)”,
(E) after
the substance “4-Methyl-aminorex” there are inserted the following
substances –
“4-methylmethylphenidate
4-Methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine
(4,4-DMAR)
(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ALD-52)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(PRO-LAD)”,
(F) after
the substance “Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine”
there is inserted the substance “Ethylnaphthidate”,
(G) after
the substance “4-hydroxybutanoic acid (4-hydroxy-n-butyric acid;
gamma-hydroxybutyric acid)” there is inserted the substance “Isopropylphenidate
(IPP or IPPD)”,
(H) after
the substance “Methylamphetamine” there is inserted the substance
“Methylnaphthidate (HDMP-28)”,
(I) after
the substance “O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydro-xylamine”
there is inserted the substance “Propylphenidate”,
(ii) for paragraph 1(b) there is substituted the following sub-paragraph –
“(b) any compound (not being a
compound for the time being specified in sub-paragraph (a)) structurally
derived from tryptamine or from a ring-hydroxy tryptamine by modification in
any of the following ways, that is to say –
(i) by
substitution at the nitrogen atom of the sidechain to any extent with alkyl or
alkenyl substituents, or by inclusion of the nitrogen atom of the side chain
(and no other atoms of the side chain) in a cyclic structure,
(ii) by
substitution at the carbon atom adjacent to the nitrogen atom of the side chain
with alkyl or alkenyl substituents,
(iii) by
substitution in the 6-membered ring to any extent with alkyl, alkoxy,
haloalkyl, thioalkyl, alkylenedioxy, or halide substituents,
(iv) by
substitution at the 2-position of the tryptamine ring system with an alkyl
substituent;”,
(iii) after
paragraph 1(p) there is added
the following sub-paragraph –
“(q) any compound (not being
clonitazene, etonitazene, nabilone, zafirlukast, or a compound for the time
being specified in sub-paragraphs (j) to (nd)) structurally related to
1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that
is to say the indole ring, the pentyl substituent, the methanone linking group
and the naphthyl ring, are linked together in a similar manner, whether or not
any of the sub-structures have been modified, and whether or not substituted in
any of the linked sub-structures with one or more univalent substituents and
where the modifications of the sub-structures are limited to any the following,
that is to say –
(i) replacement
of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole,
benzimidazole, or pyrazolo(3,4-b)pyridine,
(ii) replacement
of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl, or
(tetrahydropyran-4-yl)methyl,
(iii) replacement
of the methanone linking group with an ethanone, carboxamide, carboxylate,
methylene bridge or methine group,
(iv) replacement
of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl,
cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl,
1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1
amino-1-oxopropan-2-yl, 1-hydroxy-1-oxopropan-2-yl, or piperazinyl.”;
(b) in
Part 2 after paragraph 3 there is added the following
paragraph –
“4 A liquid
formulation –
(a) containing a botanical extract of
cannabis –
(i) with
a concentration of not more than 30 milligrams of cannabidiol per millilitre,
and not more than 30 milligrams of delta-9-tetrahydrocannabinol per
millilitre, and
(ii) where
the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3;
(b) which is dispensed through a metered dose
pump as a mucosal mouth spray; and
(c) which was approved for marketing by the
Medicines and Healthcare Products Regulatory Agency of the United Kingdom on
16th June 2010.”.
3 Misuse
of Drugs (General Provisions) (Jersey) Order 2009 amended
In the Misuse of Drugs (General Provisions)
(Jersey) Order 2009[4] –
(a) in Schedule 1 –
(i) in
paragraph 1(a) –
(A) after the substance “Bufotenine”
there is inserted the substance “1-Cyclohexyl-4-(1,2diphenylethyl)piperazine
(MT-45)”,
(B) after the word
“Cannabis” there are inserted the words “(not being the substance
specified in paragraph 10 of Schedule 4)”,
(C) after the substance
“Concentrate of poppy-straw” there are inserted the following substances –
“3,4-Dichloromethylphenidate
(3,4-DCMP)
3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide
(AH-7921)
Ethylnaphthidate”,
(D) after the substance “Etryptamine”
there is inserted the substance “Isopropylphenidate (IPP or IPPD)”,
(E) after the substance
“Methylamphetamine” there is inserted the substance “Methylnaphthidate
(HDMP-28)”,
(F) after the substance
“N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
(AB-FUBINACA)” there is inserted the substance “Propylphenidate”,
(G) after the substance “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol
(also known as O-desmethyltramadol) there is inserted the substance “2,4-dimethylazetidinyl{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin-9-yl}methanone
(LSZ)”,
(H) after the substance “4-Methyl-aminorex”
there are inserted the following substances –
“4-methylmethylphenidate
4-Methyl-5-(4methylphenyl)-4,5-dihydrooxazol-2-amine
(4,4’-DMAR)
(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
(ALD-52)
(6aR,9R)-N,N-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (AL-LAD)
(6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ETH-LAD)
(6aR,9R)-N,N-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (PRO-LAD)”,
(ii) for
paragraph 1(b) there is substituted the following
sub-paragraph –
“(b) any compound (not being a
compound for the time being specified in sub-paragraph (a)) structurally
derived from tryptamine or from a ring-hydroxy tryptamine by modification in
any of the following ways, that is to say –
(i) by
substitution at the nitrogen atom of the sidechain to any extent with alkyl or
alkenyl substituents, or by inclusion of the nitrogen atom of the side chain
(and no other atoms of the side chain) in a cyclic structure,
(ii) by
substitution at the carbon atom adjacent to the nitrogen atom of the side chain
with alkyl or alkenyl substituents,
(iii) by
substitution in the 6-membered ring to any extent with alkyl, alkoxy,
haloalkyl, thioalkyl, alkylenedioxy, or halide substituents,
(iv) by
substitution at the 2-position of the tryptamine ring system with an alkyl
substituent;”,
(iii) after
paragraph 1(u) there is added the following sub-paragraph –
“(v) any compound (not being
clonitazene, etonitazene, nabilone, zafirlukast, or a compound for the time
being specified in sub-paragraphs (l) to (pd)) structurally related to
1-pentyl-3-(1-naphthoyl)indole (JWH-018), in that the four sub-structures, that
is to say the indole ring, the pentyl substituent, the methanone linking group
and the naphthyl ring, are linked together in a similar manner, whether or not
any of the sub-structures have been modified, and whether or not substituted in
any of the linked sub-structures with one or more univalent substituents and
where the modifications of the sub-structures are limited to any the following,
that is to say –
(i) replacement
of the indole ring with indane, indene, indazole, pyrrole, pyrazole, imidazole,
benzimidazole, or pyrazolo(3,4-b)pyridine,
(ii) replacement
of the pentyl substituent with alkyl, alkenyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-yl)methyl, 2-(4-morpholinyl)ethyl,
or (tetrahydropyran-4-yl)methyl,
(iii) replacement
of the methanone linking group with an ethanone, carboxamide, carboxylate, methylene
bridge or methine group,
(iv) replacement
of the 1-naphthyl ring with 2-naphthyl, phenyl, benzyl, adamantyl, cycloalkyl,
cycloalkylmethyl, cycloalkylethyl, bicyclo[2.2.1]heptanyl,
1,2,3,4-tetrahydronaphthyl, quinolinyl, isoquinolinyl, 1 amino-1-oxopropan-2-yl,
1-hydroxy-1-oxopropan-2-yl, or piperazinyl.”;
(b) in
paragraph 1 of Schedule 2 –
(i) after
the substance “Levorphanol” there is inserted the substance “Lisdexamphetamine”,
(ii) after
the substance “Nicomorphine” there is inserted the substance
“N-methyl-1-(thiophen-2-yl)propan-2-amine (methiopropamine or MPA)”;
(c) in
Schedule 4 after paragraph 9 there is added the following
paragraph –
“10 A liquid
formulation –
(a) containing a botanical extract of
cannabis –
(i) with
a concentration of not more than 30 milligrams of cannabidiol per millilitre,
and not more than 30 milligrams of delta-9-tetrahydrocannabinol per
millilitre, and
(ii) where
the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and
1.3;
(b) which is dispensed through a metered dose
pump as a mucosal mouth spray; and
(c) which was approved for marketing by the
Medicines and Healthcare Products Regulatory Agency of the United Kingdom on
16th June 2010.”.
4 Citation
and commencement
This Order may be cited as
the Misuse of Drugs (Miscellaneous Amendments) (No. 6) (Jersey)
Order 2016 and shall come into force 7 days after the day it is made.
senator a.k.f. green, m.b.e.
Minister for Health and Social Services